VBWG ACC 2017 Sotirios Tsimikas summarises the rationale of innovative therapeutic approaches targeting Lp(a), ApoC3 or ATP citric lyase and in what stage of clinical testing they currently are.
ESC HF 2017 At the ESC HF congress in Paris, professor Voors shares the disappointing results of the RELAX-AHF, in which treatment with serelaxin in acute HF did not result in improvement in mortality and worsening HF
Various stroke subtypes have different risk profiles particularly in younger individuals, supporting a more tailored primary and secondary stroke prevention strategy in younger patients.
In a large study, based on 4-yearly questionnaires during at least 20 years, gluten intake did not significantly affect the risk of CHD, but avoidance may increase the risk via reduced whole grain intake.
ACC 2017 A substudy of ARISTOTLE showed that new users of digoxin had a four-fold risk of sudden death, and higher plasma digoxin levels were associated with higher risk, also in AF patients who used digoxin at baseline.
Expert members of AF-SCREEN propose systematic or opportunistic screening approaches for AF based on known published data, to reduce the number of strokes and death.
PCSK9 Expert Opinions Prof. Richard Hobbs states that recent data from FOURIER show that effective medical treatment to lower LDL-c reduces endpoints that are important and expensive both for individuals and for health systems.
This document updates the ACCF/AHA Heart Failure guidelines of 2013.
Strong association between elevated plasma apo CIII levels with CAD risk may be due to elevated levels of remnant lipoproteins, small dense LDL and low-grade inflammation.
In the ASCOT-LLA trial, adverse events, such as muscle pain, were associated with atorvastatin treatment in the unblinded phase, but not in de blinded phase of the trial
ACC 2017 Matthias Götberg summarises the advantages of the registry-based trial design of the randomised IFR-SWEDEHEART trial and shares the results of this study into clinical outcomes after IFR as compared with FFR.